Compare iShares MSCI South Africa ETF (EZA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Smith & Nephew plc — how do they compare? iShares MSCI South Africa ETF trades at $63.8 (market cap $455.34M), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 24.4× iShares MSCI South Africa ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares MSCI South Africa ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Africa ETF for 70 Days and Smith & Nephew plc for 121 Days on average.
| EZA | SNN | |
|---|---|---|
Market Cap | $455.34M | $11.10B |
Volume | 148,692 | 1,051,703 |
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $37.17 |
52-Week Low | $60.43 | $26.42 |
Typical Hold Time | 70 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $63.8, up 2.42% today, but technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The stock faces resistance near $64 and support at $61. Recent news highlights a brief price surge above the 50-day moving average in September but ongoing macroeconomic pressures from South Africa's exposure to commodities and financials.
The outlook remains cautious due to global reflation and high capital costs weighing on EZA's holdings. Risks include commodity price volatility and interest rate sensitivity, while potential upside hinges on stabilization in South African markets. Investors should weigh the ETF's concentrated exposures against broader emerging market uncertainties.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
